As my father used to say, in the research field we do not work for tomorrow, but for "après-demain". He founded Debiopharm in 1979, convinced of the potential of oxaliplatin, a compound in which nobody believed in but him. He taught me commitment, passion, and perseverance. Today, I am following his legacy and vision. Over the past 20 years, I have been driven by the ambition to help patients and offer them a better "après-demain". Nothing motivates me more than knowing our work can have a positive impact on people. Today more than ever, the pharmaceutical industry is at turning point in history through the convergence of science: the future of healthcare and patient quality of life is happening now and I want to be sure that Debiopharm will be at the forefront of shaping that future. Although drug development is our core activity, I believe in a broader concept of health which not only focuses on drugs and treatments, but also includes the overall patient journey: from rapid diagnostics, the right medication, effective monitoring and active support of patients is the key to a successful treatment. I have made my mission to build a solid group of companies that are ready to face the biggest challenges in healthcare. With our strategic investment fund, we invest in cutting-edge digital health, artificial intelligence, big data and diagnostic companies. In addition, with Impact Healthcare, a company created in 2019, we seek to support, help, and care for the aging population and their loss of autonomy. We have the will to invest in companies or to create public-private partnerships that can offer personalized and tailor-made healthcare. Our main strength is our independence! Freedom to help people is incompatible with shareholding. These types of decisions should not be based on the financial expectations of investors and non-family shareholders. When I joined my father at Debiopharm, my priority was to build a group solid enough to ensure sustainability and financial independence, the prerequisite of our strategic independence. Thanks to the synergy between companies, we have a long-term vision enabled by the asset management activities of Après-demain that offer us more stable incomes and mitigate the risks of Debiopharm's activities. We are and will remain a private Group.